Chemistry:AOD9604
From HandWiki
Short description: Orally active, lipolytic fragment of human growth hormone
 | This article appears to contradict the article HGH Fragment 176–191. (Learn how and when to remove this template message) |
| Names | |
|---|---|
| IUPAC name
(2S)-2-[[2-[[(4R,7S,13S,16S,19S,22S,25R)-25-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-22-(3-carbamimidamidopropyl)-13-(2-carboxyethyl)-7,19-bis(hydroxymethyl)-6,9,12,15,18,21,24-heptaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carbonyl]amino]acetyl]amino]-3-phenylpropanoic acid
| |
| Other names
H-Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH
| |
| Identifiers | |
3D model (JSmol)
|
|
| Abbreviations | YLRIVQCRSVEGSCGF |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C78H123N23O23S2 | |
| Molar mass | 1815.10 g·mol−1 |
| Related compounds | |
Related compounds
|
HGH Fragment 176–191 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
AOD9604 is an orally active, lipolytic peptide fragment of human growth hormone and derivative of the C-terminal domain of human growth hormone (HGH). It consists of HGH residues 176–191, with a tyrosine in place of the phenylalanine at the C-terminal end.[1] Human trials show that it retains the lipolytic properties of human growth hormone without stimulating IGF-1 production.[2]
Mechanism of action
AOD9604 appears to enhance lipolysis by upregulating beta-3 adrenergic receptors. Beta-3 adrenergic receptor knockout mice are unresponsive to the lipolytic effects of AOD9604.[1]
Clinical data
In a 12 week randomised trial, subjects receiving AOD9604 lost, on average, 1.8kg more than those receiving placebo.[3] Development of AOD9604 was halted following insignificant efficacy in a later 24 week trial.[3]
References
- ↑ 1.0 1.1 Heffernan, M.; Summers, R. J.; Thorburn, A.; Ogru, E.; Gianello, R.; Jiang, W. J.; Ng, F. M. (December 2001). "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice". Endocrinology 142 (12): 5182–5189. doi:10.1210/endo.142.12.8522. ISSN 0013-7227. PMID 11713213. https://pubmed.ncbi.nlm.nih.gov/11713213/.
- ↑ Stier, Heike; Vos, Evert; Kenley, David (2013-04-23). "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans" (in en). Journal of Endocrinology and Metabolism 3 (1–2): 7–15. doi:10.4021/jem157w. ISSN 1923-287X. https://www.jofem.org/index.php/jofem/article/view/157.
- ↑ 3.0 3.1 Valentino, Michael A.; Lin, Jieru E.; Waldman, Scott A. (June 2010). "Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy". Clinical Pharmacology and Therapeutics 87 (6): 652–662. doi:10.1038/clpt.2010.57. ISSN 0009-9236. PMID 20445536.
 |  |
